New precision drug targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This early-stage study tests a new drug, OKI-219, designed to attack cancer cells with a specific mutation (PI3KαH1047R). About 200 adults with advanced solid tumors or breast cancer will receive the drug alone or with other treatments. The goal is to find safe doses and see if t…
Phase: PHASE1 • Sponsor: OnKure, Inc. • Aim: Disease control
Last updated Jun 08, 2026 13:05 UTC